Has Tejvir Singh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $97,546 in general payments to Tejvir Singh, MD across 434 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tejvir Singh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tejvir Singh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tejvir Singh, MD

Hematology & Oncology · Reno, NVNPI 1932139136

Payments from drug & device makers

$97,546in general payments, 2019–2025

Across 434 payments — averaging $224.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$20K
Amgen$18K
Incyte Corporation$7K
Gilead$5K
E.r. Squibb & Sons, L.L.C.$5K
Exelixis Inc.$5K
plus $38K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	32	$20,148
Amgen	34	$17,599
Incyte Corporation	25	$6,818
Gilead(2 entities)	13	$5,312
E.r. Squibb & Sons, L.L.C.	25	$4,690
Exelixis Inc.	9	$4,609
Dova Pharmaceuticals	3	$3,920
Pfizer	24	$3,622
Merck	15	$3,507
Pharmacosmos Therapeutics Inc.	1	$2,400
Novartis	19	$2,240
Daiichi Sankyo Inc.	15	$2,006
Coherus Oncology, Inc.	2	$1,988
Lilly USA, LLC	4	$1,860
Puma Biotechnology, Inc.	3	$1,852
Beigene USA, Inc.	6	$1,647
Athenex Pharmaceutical Division, LLC	2	$1,425
Jazz Pharmaceuticals Inc.	2	$1,389
Epizyme, Inc.	2	$1,375
Seagen Inc.	4	$1,339
Takeda Pharmaceuticals U.S.A., Inc.	7	$1,229
Acerta Pharma LLC	1	$769
Beigene, Ltd.	1	$525
Astellas Pharma US Inc	16	$427
Sanofi	11	$347
Johnson & Johnson	14	$311
Genentech USA, Inc.	12	$275
Pharmacyclics LLC, An Abbvie Company	8	$242
GSK	9	$233
Mirati Therapeutics, Inc.	5	$218
Novocure GmbH	1	$200
Regeneron Healthcare Solutions, Inc.	6	$194
ASD Specialty Healthcare, LLC	2	$188
Array Biopharma Inc	7	$177
EMD Serono, Inc.	4	$169
Eisai Inc.	6	$164
Tersera Therapeutics LLC	5	$158
Ipsen Biopharmaceuticals, Inc	5	$135
Blueprint Medicines Corporation	3	$119
Bristol Myers Squibb	6	$117
Deciphera Pharmaceuticals Inc.	4	$103
Comsort, Inc	1	$100
Cardinal Health 110 LLC	1	$100
Springworks Therapeutics, Inc.	3	$90
AbbVie	4	$85
Pharmaessentia USA Corporation	3	$85
Organon	4	$77
Bayer	3	$71
Apellis Pharmaceuticals, Inc.	3	$70
Servier Pharmaceuticals LLC	3	$64
Boehringer Ingelheim	2	$63
Spectrum Pharmaceuticals Inc.	2	$61
Kyowa Kirin, Inc.	2	$50
Syndax Pharmaceuticals, Inc.	2	$49
Acrotech Biopharma Inc.	3	$40
Sun Pharmaceutical Industries Inc.	2	$38
Octapharma USA, Inc.	2	$37
EUSA Pharma (US) LLC	2	$35
Agios Pharmaceuticals, Inc.	2	$33
Stemline Therapeutics Inc.	2	$32

How this compares

$97,546 in reported general payments places this provider in the 70th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024

$4,894,461

Medicare patients

804

Services billed

187,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Reno

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →